Blood Brain Barrier Penetration and Pharmacokinetics of the Elemene in Malignant Patients.

Dalian Holley Kingkong Pharmaceutical

Status: Unknown

Conditions: Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01679847

HSZL201001

Details and patient eligibility

About

The purpose of this study is to elucidate the pharmacokinetics and the blood-brain barrier penetration of the elemene.

Enrollment: 8 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• histopathological or cytopathology diagnosis of malignancy
• heart, liver and renal function is normal
• Expected survival time is more than 3 months
• Signed informed consent

Exclusion criteria

• non cancer patient
• accepted elemene administration in 1 month
• Expected survival time is less than 3 months
• no Signed informed consent
• heart, liver and renal function is abnormal